KR102585058B1 - 인간화된 ｍ－ｃｓｆ 마우스 - Google Patents

인간화된 ｍ－ｃｓｆ 마우스 Download PDF

Info

Publication number
KR102585058B1
KR102585058B1 KR1020227013434A KR20227013434A KR102585058B1 KR 102585058 B1 KR102585058 B1 KR 102585058B1 KR 1020227013434 A KR1020227013434 A KR 1020227013434A KR 20227013434 A KR20227013434 A KR 20227013434A KR 102585058 B1 KR102585058 B1 KR 102585058B1
Authority
KR
South Korea
Prior art keywords
csf
human
mouse
cells
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227013434A
Other languages
English (en)
Korean (ko)
Other versions
KR20220054718A (ko
Inventor
앤드류 제이. 머피
션 스티븐스
초자벤단 라티남
엘리자베스 아이논
마르쿠스 지. 만츠
리차드 플라벨
조지 디. 얀코풀로스
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
예일 유니버시티
인스티튜트 포 리서치 인 바이오메드슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드, 예일 유니버시티, 인스티튜트 포 리서치 인 바이오메드슨 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Priority to KR1020237033247A priority Critical patent/KR102714361B1/ko
Publication of KR20220054718A publication Critical patent/KR20220054718A/ko
Application granted granted Critical
Publication of KR102585058B1 publication Critical patent/KR102585058B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8536—Animal models for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
KR1020227013434A 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스 Active KR102585058B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237033247A KR102714361B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161442946P 2011-02-15 2011-02-15
US61/442,946 2011-02-15
KR1020217015137A KR102390850B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
PCT/US2012/025040 WO2012112544A2 (en) 2011-02-15 2012-02-14 Humanized m-csf mice

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217015137A Division KR102390850B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033247A Division KR102714361B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스

Publications (2)

Publication Number Publication Date
KR20220054718A KR20220054718A (ko) 2022-05-03
KR102585058B1 true KR102585058B1 (ko) 2023-10-05

Family

ID=46673120

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020227013434A Active KR102585058B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020217015137A Active KR102390850B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020207012878A Active KR102256316B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020237033247A Active KR102714361B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020137020995A Active KR102061143B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020197038167A Active KR102109172B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020217015137A Active KR102390850B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020207012878A Active KR102256316B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020237033247A Active KR102714361B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020137020995A Active KR102061143B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스
KR1020197038167A Active KR102109172B1 (ko) 2011-02-15 2012-02-14 인간화된 ｍ－ｃｓｆ 마우스

Country Status (17)

Country Link
US (5) US8847004B2 (https=)
EP (3) EP3375284B1 (https=)
JP (5) JP5834097B2 (https=)
KR (6) KR102585058B1 (https=)
CN (3) CN111808879B (https=)
AU (1) AU2012217836B2 (https=)
CA (1) CA2826714C (https=)
DK (3) DK2675271T3 (https=)
ES (3) ES2948210T3 (https=)
FI (2) FI3375284T3 (https=)
IL (7) IL227704A0 (https=)
MX (3) MX338971B (https=)
MY (1) MY162984A (https=)
PT (3) PT2675271T (https=)
RU (2) RU2577978C2 (https=)
SG (3) SG10202008003VA (https=)
WO (1) WO2012112544A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2449112A1 (en) * 2009-07-01 2012-05-09 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (scid)
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
SG10202008003VA (en) 2011-02-15 2020-10-29 Regeneron Pharma Humanized m-csf mice
CN108866101A (zh) 2011-10-28 2018-11-23 瑞泽恩制药公司 人源化il-6和il-6受体
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
FI2892330T3 (fi) 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
MX377561B (es) * 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
MX384291B (es) 2013-02-20 2025-03-14 Regeneron Pharma Modificación genética de ratas.
CN103409468B (zh) * 2013-03-20 2015-08-12 中国科学院广州生物医药与健康研究院 一种免疫缺陷小鼠模型的建立方法
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
WO2014204763A1 (en) 2013-06-17 2014-12-24 3M Innovative Properties Company Process for preparing guanidino-functional monomers
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
ES2613379T3 (es) 2013-10-15 2017-05-24 Regeneron Pharmaceuticals, Inc. Animales con IL-15 humanizada
RU2671101C1 (ru) 2013-11-19 2018-10-29 Регенерон Фармасьютикалс, Инк. Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
CA2929846C (en) * 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
EP3636073B1 (en) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
NO2785538T3 (https=) 2014-05-07 2018-08-04
MX2016014995A (es) 2014-05-19 2017-03-31 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
MX373055B (es) * 2014-05-30 2020-05-20 Regeneron Pharma Animales con dipeptidil peptidasa iv (dpp4) humanizada.
HUE064960T2 (hu) 2014-12-05 2024-04-28 Regeneron Pharma Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
CN113412818B (zh) 2014-12-09 2022-11-04 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
ES2950399T3 (es) * 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
CN105994125B (zh) * 2015-04-15 2019-05-17 中国科学院广州生物医药与健康研究院 一种评价免疫缺陷小鼠模型的免疫缺陷程度的方法
EP3306313B1 (en) * 2015-05-29 2020-07-15 Central Institute For Experimental Animals Method for evaluating hematological toxicity of drug under evaluation
HK1255123A1 (zh) 2015-06-23 2019-08-02 The Jackson Laboratory 具有患者衍生异种移植物的非hla匹配的人源化nsg小鼠模型
CN105145486A (zh) * 2015-07-22 2015-12-16 中国医学科学院医学实验动物研究所 Rag2基因敲除大鼠在建立个性化肿瘤治疗模型中的应用
WO2017087780A1 (en) 2015-11-20 2017-05-26 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
SG11201806176PA (en) 2016-02-04 2018-08-30 Regeneron Pharma Non-human animals having an engineered angptl8 gene
KR101887051B1 (ko) * 2016-02-12 2018-08-10 한국과학기술원 오브젝트 탐닉행동을 활용한 동물행동 조절 방법
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
CN110740641A (zh) * 2016-11-30 2020-01-31 杰克逊实验室 具有改善的人先天免疫细胞发育的人源化小鼠模型
ES2937797T3 (es) 2017-04-17 2023-03-31 Jackson Lab Método de determinación de la toxicidad de un fármaco inmunomodulador para el uso en seres humanos
US20190098879A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
WO2020041174A1 (en) * 2018-08-20 2020-02-27 The Jackson Laboratory Method of determining toxicity of an immunomodulatory drug
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN111073907B (zh) * 2018-12-25 2025-07-29 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf1基因改造非人动物的构建方法及应用
KR102661779B1 (ko) 2019-04-04 2024-04-30 리제너론 파마슈티칼스 인코포레이티드 인간화 응고 인자 12 좌위를 포함하는 비-인간 동물
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
WO2021011853A2 (en) * 2019-07-17 2021-01-21 Yale University Genetically modified non-human animals and methods of use thereof
US11170872B2 (en) 2019-11-05 2021-11-09 Apeel Technology, Inc. Prediction of latent infection in plant products
WO2021154791A1 (en) * 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
KR20230074758A (ko) 2020-09-24 2023-05-31 더 잭슨 래보라토리 면역 세포 요법을 평가하기 위한 인간화 마우스 모델
CN113100175B (zh) * 2021-03-08 2022-07-12 北京大学人民医院 一种巨细胞病毒感染的人源化小鼠模型及其构建方法
WO2022222958A1 (en) * 2021-04-20 2022-10-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric genes
IL318159A (en) 2022-07-19 2025-03-01 Regeneron Pharma Genetically modified animal model and its use to model the human immune system
US20250255282A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200982A1 (en) 2009-10-06 2011-08-18 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) * 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
DE3853201T2 (de) 1987-12-23 1995-09-14 Univ Leland Stanford Junior Schimäre immunkompromittierende Säugetiere und ihre Verwendung.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DK0438053T3 (da) 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
WO1991016910A1 (en) 1990-05-03 1991-11-14 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
WO1991018615A1 (en) 1990-05-25 1991-12-12 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
JPH06505186A (ja) 1991-02-11 1994-06-16 オマーヤ，アユブ　ケー． 脊髄液駆動式人工器官
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
US5663481A (en) 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
JPH10503092A (ja) 1994-07-27 1998-03-24 メルク エンド カンパニー インコーポレーテッド ブラジキニンｂ２受容体が改変されたトランスジェニック非ヒト動物
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
IL132164A0 (en) 1997-04-09 2001-03-19 Chang Lung Ji Animal model for evaluation of vaccines
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
WO2001015521A1 (en) * 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
AU2066301A (en) 1999-12-09 2001-06-18 Human Genome Sciences, Inc. Il-6 like polynucleotide
AU2001290855A1 (en) 2000-09-14 2002-03-26 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002363322A1 (en) 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1452093A4 (en) 2001-11-15 2007-08-15 Kirin Brewery CHIMESE NON-MENTAL ANIMAL
JPWO2004005496A1 (ja) 2002-07-05 2005-11-04 麒麟麦酒株式会社 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
EP1539946A4 (en) 2002-09-09 2006-03-15 California Inst Of Techn METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
EP1418185A1 (en) * 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
CA2507882A1 (en) 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
CN1751236A (zh) * 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
DK2019683T4 (da) 2006-04-25 2022-08-29 Univ California Indgivelse af vækstfaktorer til behandling af CNS-lidelser
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
WO2008069659A1 (en) 2006-12-05 2008-06-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
WO2008153742A2 (en) * 2007-05-23 2008-12-18 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression
GB0718029D0 (en) * 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
AU2013204613A1 (en) 2008-12-24 2013-05-16 The Kingdom of The Netherlands, Represented by The Minister of Health, Welfare and Sport Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides
EP2448967B1 (en) 2009-06-29 2015-04-15 Ilya B. Leskov Non-human mammal model of human hematopoietic cancer
CN102725400A (zh) 2009-06-29 2012-10-10 麻省理工学院 制造人源化的非人类哺乳动物的方法
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
EP2618656B1 (en) 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
SG10202008003VA (en) 2011-02-15 2020-10-29 Regeneron Pharma Humanized m-csf mice
CN108866101A (zh) 2011-10-28 2018-11-23 瑞泽恩制药公司 人源化il-6和il-6受体
FI2892330T3 (fi) * 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
MX377561B (es) 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
TR201901782T4 (tr) 2013-09-23 2019-03-21 Regeneron Pharma İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
ES2613379T3 (es) 2013-10-15 2017-05-24 Regeneron Pharmaceuticals, Inc. Animales con IL-15 humanizada
MX2016014995A (es) 2014-05-19 2017-03-31 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
ES2950399T3 (es) 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
EP3478283A4 (en) 2016-06-29 2020-07-22 Menlo Therapeutics Inc. USE OF NEUROKININ-1 ANTAGONISTS IN THE TREATMENT OF A VARIETY OF PRURITIUS CONDITIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200982A1 (en) 2009-10-06 2011-08-18 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PNAS vol.106(51), pp.21783-21788(2009.12.22. 공개)*
PNAS vol.108(6), pp.2390-2395(2011.02.08. 공개)*
Tim Willinger et als., PNAS vol.108(6), pp.2390-2395(2011.02.08. 공개)의 Supporting Information*

Also Published As

Publication number Publication date
MX380588B (es) 2025-03-12
DK3375284T3 (da) 2023-06-12
RU2013142043A (ru) 2015-03-27
KR102109172B1 (ko) 2020-05-12
EP4233537B1 (en) 2025-07-09
JP7181911B2 (ja) 2022-12-01
KR102061143B1 (ko) 2019-12-31
US20250072406A1 (en) 2025-03-06
JP2020168023A (ja) 2020-10-15
JP6188765B2 (ja) 2017-08-30
SG10202008003VA (en) 2020-10-29
IL238781A (en) 2017-08-31
NZ708040A (en) 2016-10-28
WO2012112544A3 (en) 2012-11-15
IL239350A (en) 2017-12-31
US8847004B2 (en) 2014-09-30
DK2675271T3 (en) 2018-08-27
RU2577978C2 (ru) 2016-03-20
RU2020126649A (ru) 2022-02-10
KR20200054323A (ko) 2020-05-19
IL238781A0 (en) 2015-06-30
CA2826714C (en) 2022-11-08
KR102390850B1 (ko) 2022-04-26
CN111808879A (zh) 2020-10-23
KR20220054718A (ko) 2022-05-03
MX2013009406A (es) 2013-12-16
CA2826714A1 (en) 2012-08-23
JP6732987B2 (ja) 2020-07-29
EP2675271A4 (en) 2015-03-18
IL227704A0 (en) 2013-09-30
JP2017189180A (ja) 2017-10-19
EP3375284A1 (en) 2018-09-19
IL278385B (en) 2021-12-01
IL253743B (en) 2019-05-30
US10785966B2 (en) 2020-09-29
CN105861553A (zh) 2016-08-17
RU2730643C2 (ru) 2020-08-24
MX338971B (es) 2016-05-06
KR102256316B1 (ko) 2021-05-28
DK4233537T3 (da) 2025-08-25
JP5834097B2 (ja) 2015-12-16
KR20140020865A (ko) 2014-02-19
ES2685790T3 (es) 2018-10-11
FI3375284T3 (fi) 2023-06-15
IL288167A (en) 2022-01-01
US20170273285A1 (en) 2017-09-28
KR102714361B1 (ko) 2024-10-11
EP2675271B1 (en) 2018-06-13
IL266886B (en) 2020-11-30
EP4233537A2 (en) 2023-08-30
CN103547148A (zh) 2014-01-29
SG192606A1 (en) 2013-09-30
US20210112791A1 (en) 2021-04-22
FI4233537T3 (fi) 2025-08-27
WO2012112544A2 (en) 2012-08-23
EP3375284B1 (en) 2023-03-29
IL253743A0 (en) 2017-09-28
RU2016104468A3 (https=) 2019-06-26
US20150047061A1 (en) 2015-02-12
JP2016039818A (ja) 2016-03-24
ES2948210T3 (es) 2023-09-06
ES3040596T3 (en) 2025-11-03
PT3375284T (pt) 2023-06-28
KR20210062718A (ko) 2021-05-31
CN103547148B (zh) 2016-06-08
CN105861553B (zh) 2020-08-14
PT2675271T (pt) 2018-10-11
IL239350A0 (en) 2015-07-30
EP4233537A3 (en) 2023-09-13
KR20200003241A (ko) 2020-01-08
CN111808879B (zh) 2024-12-31
JP6505786B2 (ja) 2019-04-24
NZ613948A (en) 2015-06-26
SG10201601067WA (en) 2016-03-30
KR20230145500A (ko) 2023-10-17
JP2014510520A (ja) 2014-05-01
MX350385B (es) 2017-09-04
US12127536B2 (en) 2024-10-29
PT4233537T (pt) 2025-09-08
US20130042330A1 (en) 2013-02-14
NZ724014A (en) 2018-12-21
US9655352B2 (en) 2017-05-23
AU2012217836A1 (en) 2013-03-28
AU2012217836B2 (en) 2015-01-29
EP2675271A2 (en) 2013-12-25
JP2019122397A (ja) 2019-07-25
RU2016104468A (ru) 2018-11-22
MY162984A (en) 2017-07-31
IL266886A (en) 2019-07-31

Similar Documents

Publication Publication Date Title
US20250072406A1 (en) Humanized M-CSF Mice
AU2018213980B2 (en) Humanized M-CSF mice
RU2819731C2 (ru) Гуманизированные m-csf мыши
HK40098113B (en) Humanized m-csf mice and uses thereof
HK40098113A (en) Humanized m-csf mice and uses thereof
AU2015202020B2 (en) Humanized M-CSF mice
HK1191804A (en) Humanized m-csf mice
HK1191804B (en) Humanized m-csf mice
NZ724014B2 (en) Humanized m-csf mice

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220421

Application number text: 1020217015137

Filing date: 20210520

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220517

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220629

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230626

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230926

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230927

End annual number: 3

Start annual number: 1

PG1601 Publication of registration